Seminars in oncology
-
Seminars in oncology · Apr 2017
ReviewAngiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.